Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology.

Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington.

Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence.

Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor–associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.